Monogenic mineralocorticoid hypertension

Michael Stowasser1, Richard D Gordon

  • 1Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Australia 4102. m.stowasser@uq.qdu.au

Insights

Monogenic mutations in the mineralocorticoid pathway cause hypertension and electrolyte imbalances. Identifying genetic causes, like familial hyperaldosteronism type II, aids in diagnosing and treating primary aldosteronism.

Area of Science:

  • Endocrinology
  • Genetics
  • Hypertension Research

Background:

  • Monogenic mutations activating the mineralocorticoid pathway typically lead to hypertension, suppressed renin, and electrolyte disturbances (hypokalemia, alkalosis).
  • Specific molecular defects in steroidogenic or effector genes are known for most mineralocorticoid hypertension syndromes, aiding in understanding pathophysiology, phenotype diversity, and genetic diagnosis.
  • Familial hyperaldosteronism type II (FH-II) remains genetically unelucidated, despite being the most common and clinically significant form.

Purpose of the Study:

  • To highlight the importance of genetic factors in mineralocorticoid hypertension.
  • To emphasize the need for genetic elucidation of FH-II for improved primary aldosteronism detection.
  • To suggest that subtle genetic expressions may contribute significantly to essential hypertension.

Main Methods:

  • Review of existing literature on monogenic forms of mineralocorticoid hypertension.
  • Analysis of known genetic mutations and their phenotypic consequences.
  • Discussion of the diagnostic and therapeutic implications of genetic findings.

Main Results:

  • Established understanding of pathophysiology, phenotype diversity, and genetic diagnosis for several monogenic mineralocorticoid hypertension syndromes.
  • Identification of FH-II as a key area for future genetic research.
  • Hypothesis that undiagnosed genetic factors contribute to a substantial portion of essential hypertension.

Conclusions:

  • Genetic elucidation of FH-II is crucial for enhancing the detection of primary aldosteronism, a treatable cause of hypertension.
  • Subtle genetic variations in mineralocorticoid pathway regulation may underlie a significant proportion of cases currently diagnosed as essential hypertension.
  • Further genetic research is warranted to fully understand the spectrum of mineralocorticoid hypertension and its contribution to overall hypertensive disease.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...